Top 41-45
09 June 2011 | News
 |
Dr Reddy’s Laboratories |
The
total
biotech revenue of Dr Reddy’s Laboratories in FY 2010-11 has
grown to  82.5 crore from 62.5 crore in FY 2009-10. The company
sells
three biologic products, including Grafeel, Peg-grafeel (generic
Filgrastim) and Reditux (generic Rituximab) and has 11 biosimilars in
various stages of development and commercialization. Peg-grafeel, which
was launched in May 2011, is priced at 8,865, thus representing a
breakthrough in the pricing of this complex molecule. The company has a
fully integrated biosimilar development team including R&D,
clinical operations, medical affairs and global pharmacovigilance and
has a WHO certified cGMP manufacturing facility. Its core businesses
are pharmaceutical services and active ingredients, generics and
proprietary products. Dr Reddy’s completed the acquisition of
GlaxoSmithKline’s (GSK) US-based oral penicillin facility in Bristol,
Tennessee on Nov 23, 2010 and has got rights for the sale of Augmentin
and Amoxil brands in the US. |
| Vice
Chairman
and CEO Mr G V Prasad |
||
|
41
|
Business: Biopharmaceuticals | |
| Start-up Year: 1984 | ||
| Address:
7-1-27, Ameerpet, Hyderabad-500016 |
||
| Tel: +91-40-23731946 Fax: +91-40-23731955 Website: www.drreddys.com |
||
| Revenue: 82.5
crore* |
||
 |
Anthem Biosciences | Anthem
Biosciences,
a Bangalore-based discovery research alliance partner
(DRAP ) dedicated to supporting research efforts in the discovery of
new compounds by pharmaceutical, biotechnology, specialty chemicals,
agriculture chemicals and material science companies, registered a
growth of 47.17 percent in 2010-11 as its revenue touched 78 crore. In
2009-10, the company reported revenue worth 53 crore. Anthem
Biosciences has adopted several business models like full time
equivalent (FTE) and project basis, depending on the complexity of the
task and project. This has helped the company witness a significant
growth since its inception in 2007. Presently, Anthem employs more than
200 people. Apart from modern, well equipped laboratories, the company
has a cGMP kilo lab and a versatile GMP pilot plant. In the field of
discovery research, the firm provides services for generation of hits,
transforming hits to leads and optimization of leads. |
| CEO Mr Ajay Bharadwaj |
||
|
42
|
Business: Discovery services, nutritional products, enzymes | |
| Start-up
Year: 2007 |
||
| Address:
49, Canara Bank Road, Bommasandra Industrial Area Phase I, Hosur Road, Hebbagodi, Bangalore – 560037 |
||
| Tel: +91-80-66724000 Fax: +91-80-266724020 Website: www.anthembio.com |
||
| Revenue: 78
crore |
||
 |
Wyeth India (now a subsidiary of Pfizer India) | Wyeth
India,
a subsidiary of Pfizer India, clocked an estimated revenue of
73.35 crore. In 2010, Prevenar 13
(manufactured by Wyeth and marketed
by Pfizer) was launched in India, as advanced pneumococcal conjugate
vaccine for infants and young children. However, the price of this
advanced product is the same as its predecessor, Prevenar 7-3,800 for
a single dose. Presently, Prevenar 13, has been launched in 30
countries and registered in 98 countries. Wyeth has been in talks with
the Indian Government to include the vaccine in the National
Immunization Programme. It has a strong presence in oral
contraceptives, folic acid, depilatory cream, hormone therapy and
invasive pneumococcal vaccines. Enbrel, a breakthrough treatment for
rheumatoid arthritis; Rapamune, an immuno suppressant for the
prevention of rejection after renal transplant, and Tygacil, the
world’s first glycilcycline antibiotic, are among internationally known
products launched by Wyeth in India. |
| MD Mr Kewal Handa |
||
|
43
|
Business: Biologics, animal healthcare products & consumer healthcare | |
| Start-up Year: 2003 | ||
| Address:
Level 6&7, Platina, Plot no C-59, ‘G’ Block, Bandra-Kurla Complex,
Bandra East, Mumbai -400098 |
||
| Tel: +91-22-24935211 Website: www.wyethindia.com |
||
| Revenue: 73.35
crore* |
||
 |
Rossari Biotech | Rossari
Biotech
clocked an estimated total revenue sales of 72 crore in FY
2010-11 as compared to 55.38 crore in 2009-10. It is an ISO
9001: 2000
company and manufactures enzymes for textile processing, high
concentrates and standard formulations of neutral cellulose, acid
cellulose, engineered acid cellulose amylases, high temperature stable
amylases and multizyme formulations for bioscouring, wool and silk
processing and print washing. It exports its products to several
countries including, Sri Lanka, Bangladesh, UAE, Australia, Malaysia,
Kenya, New Zealand, Jordan, China, Venezuela and Nepal. Rossari’s new
product range includes Flameshield, Fragma, Hydrogard, Snocool and
Fabshield. Rossari set up an R&D center for biotechnology at Navi
Mumbai to explore the potential of new molecules and manufacture new
products as well as to optimize the processes. It has entered into
collaborations with firms and is looking at nutraceuticals as a
potential growth area. |
| Director Mr Sunil Chari |
||
|
44
|
Business: Production and marketing of industrial enzymes | |
| Start-up Year: 1997 | ||
| Address:
401 Omega, Main St, Hiranandani Gardens, Powai, Mumbai - 400076 |
||
| Tel: +91-22-25709200 / 01 Fax: +91-22-25709210 Website: www.rossari.com |
||
| Revenue: 72
crore* |
||
 |
Ocimum Biosolutions | Ocimum
Biosolutions
witnessed a decline in its revenue from 76 crore in 2009-10 to 65 crore in 2010-11. Ocimum offers solutions spanning bioresearch design and execution data analytics and insights; laboratory, sample and data management; and integrated solutions. Ocimum received funds worth 36.12 crore from its
existing shareholders, in order to cater to the growing demand for its
integrated genomic services and to enhance its Research as a Service
(RaaS) platform. Part of the funds would be utilized for completing a
state-of–the art integrated campus in Patancheru, Hyderabad, a 360,000
sq ft facility spread across four blocks. Last year, Ocimum also
started providing BioIT Consulting Services to help life science
organizations in their R&D. It also launched its quantitative
real-time polymerase chain reaction (qRT-PCR) services in India. This
technology is already in use at Gene Logic, an Ocimum Biosolutions
company. |
| CEO Ms Anu Acharya |
||
|
45
|
Business: Bioinformatics tools and services | |
| Start-up
Year: 2000 |
||
| Address: 6th Floor, Reliance Classic Road No. 1, Banjara Hills, Hyderabad - 500 034 |
||
| Tel: +91-40-66986700 Fax: +91-40-66627205 Website: www.ocimumbio.com |
||
| Revenue: 62
crore |
||
